Thymic epithelial tumor clinical trials

The registry lists 26 studies for Thymic epithelial tumor across 6 countries. 19 are recruiting or about to start. 20 of them are mainly about Thymic epithelial tumor (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-16.

Get an email when these change. Save the Thymic epithelial tumor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting: 12
Not yet recruiting: 7
Status unknown: 4
Active, not recruiting: 1
Completed: 1
Terminated: 1

Phase

Phase 2: 15
Phase 3: 1
Phase 1: 1

Where

China: 14
Korea, Republic of: 3
United States: 2
France: 1
Taiwan: 1
Netherlands: 1

Who runs them

Samsung Medical Center (3) · Shanghai Zhongshan Hospital (3) · National Cancer Institute (NCI) (2) · Shanghai Cancer Hospital, China (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Jian Chen (2) · Tang-Du Hospital (1) · Shanghai Pulmonary Hospital, Shanghai, China (1)

What is being tested here

Drugs under test in Thymic epithelial tumor studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Paclitaxel	1	1	2
Albumin-Bound Paclitaxel	1	1	1
Carboplatin	1	1	1
Apatinib	1	0	1
Imifoplatin	1	0	1
Cyclophosphamide	1	0	1
Fludarabine	1	0	1
AP 1903 reagent	1	0	1
Bintrafusp alfa	0	0	1
Cisplatin	0	0	1

Coming up

1phase 3 study under way

7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Dec 2026Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma · National Cancer Institute (NCI)
Dec 2026RATT Vs. VATT for Early-stage TETs · Shanghai Zhongshan Hospital
Feb 2027The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor · Jian Chen
Jun 2027Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma · Beijing Biotech
Jun 2027Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors · Tianjin Medical University Cancer Institute and Hospital
Aug 2027Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · Erasmus Medical Center
Nov 2027Hypofractionated Radiotherapy for Thymic Epithelial Tumors · Rongrong Zhou

Who these studies take

Of the 12 Thymic epithelial tumor studies recruiting now, 5 (42%) set no upper age limit and 5 (42%) stop at 75 or younger. 3 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 12
Age	Women	Men
10	2 (17%)	2 (17%)
18	12 (100%)	12 (100%)
30	12 (100%)	12 (100%)
40	12 (100%)	12 (100%)
50	12 (100%)	12 (100%)
65	12 (100%)	12 (100%)
75	10 (83%)	10 (83%)
85	6 (50%)	6 (50%)

Across all 26 studies, recruiting or not: 35% stop at 75 or younger and 4% at 65; 23% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 26 of 26. search them.